Skip Navigation


Rheumatology Advance Access originally published online on July 1, 2008
Rheumatology 2008 47(10):1441-1443; doi:10.1093/rheumatology/ken242
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
47/10/1441    most recent
ken242v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hyrich, K. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hyrich, K. L.
Related Collections
Right arrow Pharmacology
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

EDITORIALS

The British Society for Rheumatology Biologics Register: 6 years on

K. L. Hyrich1, K. D. Watson1, D. A. Isenberg2, D. P. M. Symmons1 on behalf of the BSR Biologics Register

1ARC Epidemiology Unit, University of Manchester, Manchester and 2Centre for Rheumatology Research, Division of Medicine, UCL, London, UK

Correspondence to: K.L. Hyrich, ARC Epidemiology Unit, Stopford Building, University of Manchester, Oxford Road, Manchester M13 9PT, UK. E-mail: kimme.hyrich@manchester.ac.uk

The first 150 words of the full text of this article appear below.

The introduction of anti-TNF and other biological therapies for the management of patients with RA has significantly improved the outcome for patients with severe disease. However, despite demonstrated safety compared with placebo in early clinical trials, there were still many uncertainties about their long-term safety, particularly with respect to serious infection and malignancy. There was also concern about rare and unexpected adverse events. In contrast, the possibility existed that by reducing levels of inflammation it might be possible to reduce the risk of atherosclerosis. Against this background, the British Society for Rheumatology (BSR) proposed to develop a large prospective epidemiological study, to monitor patients with RA receiving these drugs in the UK.

History and structure of the BSR Biologics Register

The BSR Biologics Register (BSRBR) was launched in October 2001. The primary aim of this study was to investigate the long-term outcome of patients with RA treated with biologic agents with particular reference to safety. The study was . . . [Full Text of this Article]

Sample size and patient recruitment

Study design and patient follow-up

What have we learned so far?

Anti-TNF treatment effectiveness

Effectiveness of anti-TNF therapy
Anti-TNF switching

Drug safety

Serious infections
Myocardial infarction
Pregnancies
Malignancy

BSRBR—the future


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
K. L. Hyrich, C. Deighton, K. D. Watson, BSRBR Control Centre Consortium, D. P. M. Symmons, M. Lunt, and on behalf of the British Society for Rheumatology
Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity
Rheumatology, October 1, 2009; 48(10): 1323 - 1327.
[Abstract] [Full Text] [PDF]